On this page
What it is
A synthetic analogue of growth-hormone-releasing hormone, modified to resist enzymatic breakdown so it survives long enough to act.
How it is proposed to work
Binds the GHRH receptor on the pituitary, stimulating release of endogenous growth hormone in a pulsatile pattern. Because it acts upstream, the resulting pulse is subject to normal feedback in a way that exogenous growth hormone is not — this is the pharmacological argument for the whole class.
Approved medical uses
Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, in jurisdictions where it holds an approval. Not approved for muscle building, general fat loss, anti-ageing, or athletic performance.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Randomised controlled trial2010n = 806
Pooled analysis of two phase 3 randomised trials in HIV patients with excess abdominal fat
Finding. The main outcome measure was percent change in visceral adipose tissue at 26 weeks: it fell significantly against placebo (P < 0.001), a treatment effect of -15.4%, while abdominal subcutaneous adipose tissue showed no significant change (P = 0.08, treatment effect -0.6%). Mean IGF-I rose significantly versus placebo (P < 0.001). Triglycerides (treatment effect -12.3%) and the cholesterol to HDL ratio (-7.2%) also fell significantly against placebo (both P < 0.001). Treatment was reported as generally well tolerated, with no clinically meaningful between-group differences in glucose parameters at 26 and 52 weeks.
Limitation. A pooled analysis of two trials rather than a single trial, in one clinical population: ART-treated HIV patients with excess abdominal fat. Visceral fat reduction in that population does not establish body-composition benefit in a metabolically healthy person. The 52-week figures come only from the subgroup re-randomised to continue treatment, not from the whole cohort.
- Randomised controlled trial2008
Discontinuation at week 26, followed to 52 weeks
Finding. In the 26-week extension of a randomised placebo-controlled trial in HIV patients with central fat accumulation on antiretroviral therapy, patients were re-randomised at week 26 either to continue tesamorelin or to switch to placebo. "Upon discontinuation of tesamorelin, VAT reaccumulated", and the authors conclude that although the effects on visceral fat are sustained during treatment for 52 weeks, "these effects do not last beyond the duration of treatment". The change in visceral adipose tissue was sustained at 18% over 52 weeks of treatment (P < 0.001 versus baseline). Tolerability was reported on both sides: tesamorelin was "generally well tolerated", with adverse and serious adverse events during the extension comparable with the initial phase and glucose changes over 52 weeks "not clinically significant", while high-density lipoprotein "decreased minimally over 52 weeks".
Limitation. Everyone studied was an HIV patient with central fat accumulation on antiretroviral therapy, so this says nothing about what happens on stopping in anyone else — including the healthy adults who account for most real-world use. The discontinuation result comes from a re-randomised extension arm, the smallest of the three re-randomised groups (n = 50), rather than a standalone trial, and the abstract prints arm sizes only, not a single enrolled total.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionEstablished
Raises IGF-1, and glucose intolerance has been observed. Monitoring is part of the approved labelling for a reason.
- WatchEstablished
Injection-site reactions and arthralgia are commonly reported in trials.
- SeriousEstablished
Grey-market 'tesamorelin' is not the approved product. Identity, purity and concentration are unverified, and the approval provides no assurance whatsoever about material bought outside it.
Known interactions and contraindication considerations
- Effects on glucose handling are relevant to anyone with diabetes or impaired glucose tolerance.
- Contraindication considerations exist around active malignancy in the approved labelling, given the IGF-1 rise.
- Concurrent use with other GH secretagogues has not been characterised.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Approved as of 1 Jun 2026 |
The approval is for one indication in one population. Use for muscle building or general body composition is outside it entirely. |
European Union EMA | Not approved as of 1 Jun 2026 | Marketing authorisation status has changed over time in the EU. Verify current standing directly with the EMA before relying on this. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Not approved. Confirm current CDSCO status before assuming availability. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Visceral fat reduction outside the approved indication
What is run
Daily administration, usually pre-sleep, in blocks — by people without HIV-associated lipodystrophy, targeting abdominal fat.
Their mechanistic reasoning
That because it demonstrably reduces visceral adipose tissue in trials, it should do the same in anyone carrying visceral fat.
Reported in the community’s own terms. Not our position.
Stacked with
- Secretagogues—Added for a combined pulse, though tesamorelin is already a GHRH analogue.
Regimen shape
- Dose
- figure withheld
- Scale
- Milligram-scale
- Route
- Subcutaneous injection
- Frequency
- Daily
- Timing
- Pre-sleep
- Duration
- Extended blocks, months
Our read
This is the most understandable extrapolation on this page and still an extrapolation. HIV-associated lipodystrophy is a specific pathology of fat distribution, and an agent that corrects a disordered state does not necessarily produce the same effect in a normal one. The trial data is genuinely strong for what it studied. It is being asked to support a claim it never tested. Worth noting too that visceral fat returned toward baseline after treatment stopped in follow-up — this is not a course you finish.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Respected for having a real approval behind it, which carries weight in the discussion. Enthusiasm is tempered by cost and by reports that the effect regresses after stopping.
Commonly reported as helping
- Reduction in abdominal fat over months, reported by people using it long enough
- Better sleep, as with other GHRH analogues
Also reported, when it goes wrong
- Cost, the most common complaint
- Joint aches and fluid retention
- Regain of abdominal fat after stopping, matching the trial follow-up data
- Effect described as slow and requiring months of commitment
Why these reports can mislead
People running an expensive months-long protocol are usually also dieting and training, and are heavily invested in it having worked. Visceral fat is not visible or measurable without imaging, so most reports are about how someone looks — which tracks total fat loss, not the specific compartment.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Glucose intolerance is in the approved labelling for a reason. Monitor it.
- Grey 'tesamorelin' is not the approved product, and the approval offers no assurance about it.
- The effect regresses after stopping, which makes this an indefinite commitment rather than a course.
Active clinical trials
No registered trials currently tracked for Tesamorelin.
What remains unknown
The questions that would change our assessment if they were answered.
- Does visceral fat reduction in lipodystrophy translate to any benefit in people without it?
- What are the long-term consequences of sustained IGF-1 elevation in a non-deficient adult?
- Is the effect on visceral fat maintained at all without continuous treatment?
References
- 1.Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010.PMID 20554713doi
- 2.Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28.PMID 18690162doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created. Regulatory table flags that EU standing has changed over time and must be re-verified.
Spotted something wrong? Tell us — we publish corrections.